Investment Rating - The investment rating for the company is "Outperform the Market" [6][4] Core Insights - The company is expected to achieve a 61% year-on-year increase in adjusted net profit for 2024, with total revenue projected at 2.08 billion yuan, reflecting an 8.8% decline [1][9] - The company has improved its profitability significantly through operational efficiency, with an adjusted net profit margin of 8.2%, up 3.6 percentage points year-on-year [2][15] - The company has expanded its AI capabilities in both C-end and B-end services, enhancing user experience and operational efficiency [3][16] Financial Performance Summary - In 2024, the company achieved total revenue of 2.08 billion yuan, down 8.8% from the previous year, while adjusted net profit reached 1.33 billion yuan, compared to 7.5 million yuan in 2023 [1][9] - The fourth quarter of 2024 saw revenue of 564 million yuan, a decrease of 10.6%, but an adjusted net profit of 47.59 million yuan, a significant recovery from a loss of 39.54 million yuan in the same period last year [1][9] - The gross profit margin for 2024 was 76.1%, an increase of 1.8 percentage points year-on-year, indicating effective cost control measures [2][15] Business Segment Analysis - Revenue from B-end services (talent acquisition for enterprises) was 1.76 billion yuan, down 12.9%, with a decline in the number of paying enterprise clients [2][10] - C-end services (talent development for individuals) generated 318 million yuan, a 23.1% increase, driven by improved conversion rates for high-ticket courses [2][10] - The company reported a total of 780 million job postings, a decrease of 6.0% year-on-year, indicating ongoing challenges in the recruitment market [2][10] Future Outlook - The company maintains profit forecasts of 185 million yuan for 2025 and 211 million yuan for 2026, with a new forecast of 237 million yuan for 2027, reflecting growth rates of 39%, 14%, and 12% respectively [4][16] - The company is expected to benefit from structural growth in specific sectors such as technology and manufacturing, as well as the maturation of its AI products [4][16]

Investment Rating - The report maintains a "BUY" rating for Akeso, indicating a potential return of over 15% over the next 12 months [15]. Core Insights - Akeso's FY24 results showed strong cost controls despite a revenue shortfall, with total revenue of RMB2.1 billion, including RMB2.0 billion from product sales, representing a 25% YoY increase [8]. - The company is expected to see product sales surge by 60% YoY to RMB3.3 billion in FY25, driven by the inclusion of AK104 and AK112 in the National Reimbursement Drug List (NRDL) [8]. - AK112 is positioned as a next-generation immuno-oncology (IO) therapy, with pivotal clinical data demonstrating a meaningful progression-free survival (PFS) benefit in a Phase 3 trial against Keytruda for first-line PD-L1-positive non-small cell lung cancer (NSCLC) [8]. - The report highlights ongoing clinical trials for AK112 in various cancer types, including triple-negative breast cancer (TNBC) and pancreatic cancer, indicating a broad first-line strategy [8]. - The target price for Akeso has been raised from HK$58.97 to HK$102.61, reflecting increased sales projections for AK112 [8]. Financial Summary - For FY23A, Akeso reported revenue of RMB4,526 million, with a YoY growth of 440.3%, followed by a projected revenue of RMB2,124 million for FY24A, reflecting a decline of 53.1% [2]. - The net profit for FY23A was RMB2,028.3 million, with a projected net loss of RMB501 million for FY24A [2]. - R&D expenses are projected to be RMB1,306 million for FY25E, increasing to RMB1,937 million by FY27E [2]. - The company held a cash balance of RMB7.3 billion at the end of FY24, sufficient to support ongoing R&D and future commercial expansion [8]. Share Performance - Akeso's current market capitalization is HK$77,191.5 million, with a current price of HK$86.00 and a target price indicating a 19.3% upside [3]. - The stock has shown strong performance, with a 1-month absolute return of 17.9% and a 3-month return of 41.7% [5]. Valuation - The DCF valuation estimates the equity value at RMB 85,652 million, translating to a DCF per share of RMB 95.43 or HK$ 102.61 [9]. - The report includes a sensitivity analysis indicating how changes in the weighted average cost of capital (WACC) and terminal growth rate affect the target price [10].

Investment Rating - The report maintains a "Buy" rating for the company [7][8]. Core Insights - The company reported a revenue growth of 30.1% year-on-year to 3.02 billion RMB and an adjusted net profit growth of 31.4% to 400 million RMB, exceeding profit expectations by 3.1% [1][2]. - The company is expanding its offline store network, adding 21 new stores in 2024, significantly up from 9 in 2023, and now operates 78 stores across 20 cities in China and Singapore [1][7]. - The management expects a revenue growth of 25% year-on-year in 2025, with adjusted profit growth of no less than 20% [1][7]. Financial Performance - For FY23A, the company achieved a sales revenue of 2,323 million RMB, with a projected increase to 3,022 million RMB in FY24A [2]. - The adjusted net profit for FY23A was 305 million RMB, expected to rise to 400 million RMB in FY24A [2]. - The adjusted earnings per share (EPS) for FY24A is projected at 1.64 RMB, with a market average estimate of 1.93 RMB for FY25E [2]. Valuation - The target price is set at 52.38 HKD, representing a potential upside of 57.5% from the current price of 33.25 HKD [3][7]. - The report adjusts the DCF-based target price, reflecting a WACC of 10.2% and a perpetual growth rate of 3.0% [10][7]. Growth Strategy - The company is leveraging AI technology to enhance service efficiency and patient care, with plans to launch AI-powered services to improve the productivity of scarce medical resources [7][8]. - The management aims to increase overseas revenue to 150-200 million RMB by 2025, focusing on expanding in first-tier cities in China and entering new markets [7][8]. Shareholder Returns - The company returned 420 million RMB to shareholders in 2024 through dividends and buybacks, amounting to 137% of its net profit for the year [7][8]. - The management anticipates maintaining a dividend payout ratio of over 30% in the future [7].

证券研究报告 | 2025年04月02日 固生堂（02273.HK） 优于大市 2024 年业绩维持高增速，AI 赋能有望拓展全新增长空间 2024 年公司收入维持高增速，AI 赋能有望带来业务能力提升。2024 年公司 实现营收 30.22 亿元（+30.1%），溢利净额 3.07 亿元（+21.6%），经调整 溢利净额 4.00 亿元（+31.4%）。2024 年公司旗下医疗机构延续 2023 年高 速增长的态势，彰显了公司业务的发展韧性；公司保持外延迅速扩张的节奏， 拓展国内的覆盖范围及市场份额，同时于上半年进军新加坡市场，迈出国际 化第一步。凭借内生增长和外延并购的双轮驱动，以及线下医疗机构和线上 健康平台相结合的业务模式，公司民营中医连锁服务机构龙头地位日渐稳 固。此外，叠加公司将推出的名医"AI 分身"为公司的诊疗质量和水平带来 的提升，公司未来增长势头依然强劲。 客户群持续增长，诊疗量与会员人数同比提升。按营收拆分来看，医疗健康 解决方案 2024 年实现收入 29.88 亿元（+30.6%），占总收入的 98.9%。2024 年全年，公司新增客户 88.9 万人，总就诊人次达到 541.1 万 ...

2025 年 4 月 2 日 招银国际环球市场 | 睿智投资 | 公司更新 固生堂 (2273 HK) AI 赋能中医服务龙头 资料来源：公司资料、彭博及招银国际环球市场预测 | 目标价 | 52.38 港元 | | --- | --- | | (此前目标价 | 56.50 港元) | | 潜在升幅 | 57.5% | | 当前股价 | 33.25 港元 | 中国医药 武 煜, CFA (852) 3900 0842 jillwu@cmbi.com.hk 黄本晨, CFA huangbenchen@cmbi.com.hk 公司数据 固生堂发布 24 年度业绩，收入同比增长 30.1%至 30.2 亿元，经调整净利润同比 增长 31.4%至 4.0 亿元。公司的收入符合我们的预期，但利润端比我们的预测高 3.1%。公司业绩在医保监管趋严的情况下保持了高速的增长，体现出固生堂作为 龙头企业的合规性以及强劲发展势头。受益于强劲增长的客户需求，公司线下收 入同比增长 35%，其中老店收入同比增长 28%，门诊人次同比增长 25.9%，客单 价同比增长 3.3%。公司持续推进医联体合作，全年新增 8 家医联体合作单位。 ...

来源：最闻，山西证券研究所 | 市场数据：2025 年 3 月 | 31 | 日 | | | --- | --- | --- | --- | | 收盘价（港元）： | | | 729.00 | | 年内最高/最低（港元）： | | | 798.00/60.950 | | 流通股/总股本（亿股）： | | | 0.95/1.68 | | 流通市值（亿港元）： | | | 690.91 | | 总市值（亿港元）： | | | 1,227.39 | 来源：最闻，山西证券研究所 黄金珠宝 老铺黄金（06181.HK） 增持-A(维持) 分析师： 王冯 执业登记编码：S0760522030003 邮箱：wangfeng@sxzq.com 孙萌 执业登记编码：S0760523050001 邮箱：sunmeng@sxzq.com 2024 年营收业绩强劲增长，2025 年推动品牌出海 2025 年 4 月 1 日 公司研究/公司快报 事件描述 3 月 31 日，公司披露 2024 年年报，2024 年，公司实现收入 85.06 亿元，同比增长 167.5%，实现归母净利润 14.73 亿元，同比增长 253.9%。公司董事 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to achieve steady growth in core products in 2024, with new drugs potentially providing flexibility in revenue generation [5][7] - The company reported a total revenue of 9.108 billion RMB in 2024, representing a year-on-year growth of 16.5%, with drug sales contributing 8.928 billion RMB, also up by 16.8% [7] - The net profit attributable to shareholders reached 2.09 billion RMB, marking a significant increase of 34.9% year-on-year [7] - Key products such as Tevizo and Mandi are experiencing robust growth, with Tevizo sales projected at 5.06 billion RMB in 2024, reflecting a 20.4% increase [7] - The company has a promising pipeline of innovative drugs, including the PD1/VEGF dual antibody, which shows potential for high returns from overseas markets [7] Financial Summary - Revenue projections for the company are as follows: 10.102 billion RMB in 2025, 11.164 billion RMB in 2026, and 12.430 billion RMB in 2027, with growth rates of 10.9%, 10.5%, and 11.3% respectively [6][8] - The net profit attributable to shareholders is forecasted to be 2.343 billion RMB in 2025, with a growth rate of 12.1% [6][8] - The company's price-to-earnings ratio (P/E) is projected to be 12.42 in 2025, decreasing to 9.68 by 2027 [6][8] - The company aims for a target market value of 40 billion RMB, supported by steady growth in core business and innovative products [7]

2025 年 04 月 01 日 赢家时尚 (03709) ——逆境之下规模稳定，线上渠道表现亮眼 报告原因：有业绩公布需要点评 增持（维持） 上 市 公 司 公 司 点 评 / 公 司 点 评 纺织服饰 | 市场数据： | 2025 年 04 月 01 日 | | --- | --- | | 收盘价（港币） | 7.60 | | 恒生中国企业指数 | 8537.34 | | 52 周最高/最低（港币） | 13.68/7.33 | | H 股市值（亿港币） | 53.51 | | 流通 H 股（百万股） | 704.05 | | 汇率（人民币/港币） | 1.0839 | 一年内股价与基准指数对比走势： -41% 9% 59% 04/02 05/02 06/02 07/02 08/02 09/02 10/02 11/02 12/02 01/02 02/02 03/02 HSCEI 赢家时尚 资料来源：Bloomberg 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 刘佩 A0230523070002 liupei@swsresearch.com 研究支持 刘 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Insights - The company reported a revenue of 86.4 billion yuan for 2024, a year-on-year increase of 7.7%, but the net profit attributable to shareholders fell to 1.04 billion yuan, a decline of 67.3% [1][4]. - The decline in net profit is primarily attributed to the downturn in the real estate market, with a gross margin of 10.5% for 2024, down 4.8 percentage points year-on-year [2]. - The company demonstrated stronger sales performance compared to peers, with a contract sales amount of 114.5 billion yuan in 2024, a decrease of 19.4%, while the top 10 real estate companies saw a decline of 24.4% [2]. - The company has set a sales target of 120.5 billion yuan for 2025, representing a 5.2% increase compared to the 2024 sales completion [2]. Financial Performance - The company maintains a healthy financial position, with key financial metrics remaining in the green zone as of the end of 2024. The asset-liability ratio, net debt ratio, and cash-to-short-term debt ratio are 68.1%, 51.7%, and 2.1 times, respectively [3]. - The total borrowings amount to 103.9 billion yuan, a slight decrease of 0.5% year-on-year, with short-term debt accounting for 22% of total borrowings [3]. - The weighted average borrowing cost has decreased to 3.49%, down by 0.33 percentage points year-on-year [3]. Future Projections - The company is expected to experience a bottoming phase in settlement performance for 2024-2025, with potential recovery in profit performance as high-margin projects are recognized and impairment pressures ease [4]. - Projected net profits for 2025-2027 are estimated at 1.02 billion yuan, 1.24 billion yuan, and 1.36 billion yuan, with year-on-year growth rates of -1.9%, +21.4%, and +10.1%, respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue growth of over 30% in 2024, with total revenue reaching 3.885 billion yuan (up 34.6% year-on-year) and a net profit of 881 million yuan (up 33.0% year-on-year) [4][5] - The company is expected to continue its strong performance, with projected net profits for 2025-2027 at 1.179 billion, 1.536 billion, and 1.939 billion yuan respectively, reflecting a compound annual growth rate of approximately 33.9% [4][7] - The company's gross margin for 2024 was 84.4%, with a stable expense ratio across sales, management, and R&D [5][7] Financial Summary and Valuation Metrics - Revenue and net profit projections for 2025 are 5.184 billion yuan and 1.179 billion yuan respectively, with an expected EPS of 2.41 yuan [7] - The company's P/E ratios for 2025, 2026, and 2027 are projected to be 41.9, 32.2, and 25.5 respectively, indicating a favorable valuation trend [7] - The company maintains a high return on equity (ROE) of 32.7% for 2025, reflecting strong profitability [7]